Related Experiment Video

Updated: Jun 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Hypothesis: how do JAK2-inhibitors work in myelofibrosis

Ruben Mesa1, Robert Peter Gale

  • 1Mayo Clinic, Scottsdale, AZ, USA.

Leukemia Research
|May 20, 2009
PubMed

Insights

Janus kinase 2 (JAK2)-inhibitors effectively manage myelofibrosis symptoms and spleen size. These drugs primarily impact normal cells, not abnormal ones, suggesting a novel therapeutic approach for myelofibrosis.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myelofibrosis is a serious bone marrow disorder characterized by abnormal cell growth.
  • Janus kinase 2 (JAK2)-inhibitors are a class of drugs used to treat myelofibrosis.
  • The precise mechanism of action for JAK2-inhibitors in myelofibrosis is not fully understood.

Purpose of the Study:

  • To investigate the effects of JAK2-inhibitors on spleen enlargement and clinical symptoms in myelofibrosis patients.
  • To determine the impact of JAK2-inhibitors on various hematological parameters and bone marrow fibrosis.
  • To explore whether JAK2-inhibitors' efficacy differs in patients with and without the JAK2 mutation.

Main Methods:

  • Clinical assessment of spleen size and symptoms in myelofibrosis patients treated with JAK2-inhibitors.
  • Monitoring of white blood cell count, anemia, and platelet levels.
  • Evaluation of bone marrow fibrosis.
  • Analysis of treatment response in patients with and without the JAK2 mutation.

Main Results:

  • JAK2-inhibitors demonstrated rapid reduction in spleen enlargement and clinical symptoms.
  • Little to no effect was observed on white blood cell count, anemia, decreased platelets, or bone marrow fibrosis.
  • JAK2-inhibitors were effective in both patients with and without the JAK2 mutation.

Conclusions:

  • The primary therapeutic effect of JAK2-inhibitors in myelofibrosis appears to target normal hematopoietic clones rather than abnormal ones.
  • This suggests a potential mechanism involving the modulation of the normal stem cell environment.
  • Further research is warranted to elucidate the detailed mechanisms and optimize JAK2-inhibitor therapy.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...